Skip to content
DataLookout
Start free
Menu

ENDURANCENCT07821112

Phase II Elderly/Frail Pts With Newly Diagnosed or Recurrent Malignant Glioma Treated With Cesium-131 GammaTile®

StatusNot Yet Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Site contact updated
    • Study title shortened, about 1 word
  2. Study First Submitted
  • Minor: routine updates

Endpoints

Primary

Percentage of Participants who were able to receive the GammaTile Implant
Timeframe: 28 days
Number of Participants with Treatment-related Adverse Events
Timeframe: 24 months

Secondary (2)

Progression-Free Survival (PFS)
Overall Survival (OS)

Arms and interventions

Newly Diagnosed Elderly or Frail GlioblastomaExperimental

GammaTile®

Recurrent Elderly or Frail GlioblastomaExperimental

GammaTile®

Newly Diagnosed Frail (Non-GBM) Malignant GliomaExperimental

GammaTile®

Recurrent Frail (Non-GBM) Malignant GliomaExperimental

GammaTile®

Devices: GammaTile®

Sites

1 site in 1 country

  • Chao Family Comprehensive Cancer Center, University of California, IrvineOrange, California, United States